Corporate strategy
Algeta’s strategy is to build a commercial operation as well as expand its portfolio of oncology product candidates.
Latest releases
Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO
16 May 2013 at 12:00
Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA
15 May 2013 at 12:00
Upcoming events
38th Annual dbAccess Health Care Conference
29-31 May 2013, Boston, USA
Jefferies 2013 Healthcare Conference
3-6 Jun 2013, NYC, USA
Financial calendar
Presentation of the second quarter report
28 Aug 2013
Presentation of the third quarter report
6 Nov 2013
Investor relations
Through targeted investor relations activities, Algeta aims to provide accurate, timely, and consistent communications about Algeta’s status and progress, and to treat all institutional investors, private shareholders, and analysts equally with regard to information.
All important and relevant news is relayed in the form of notices to the Oslo Stock Exchange (OSE) and through press releases. Such information is distributed without delay and simultaneously to the capital markets and the media, and is also published on the Company’s website.
Management
Algeta is managed by a team of experienced pharmaceutical professionals, based in Norway and the US.
Contact us
If you'd like to know more about Algeta and our research, please do get in touch – we'd love to hear from you.